Provided by Tiger Fintech (Singapore) Pte. Ltd.

Enliven Treateutics

22.45
-0.3300-1.45%
Post-market: 22.450.00000.00%16:10 EDT
Volume:343.52K
Turnover:7.77M
Market Cap:1.29B
PE:-11.62
High:23.21
Open:22.53
Low:21.99
Close:22.78
Loading ...

Enliven Therapeutics Inc. COO Anish Patel Reports Disposal of Common Shares

Reuters
·
10 Jul

Enliven price target raised to $48 from $40 at H.C. Wainwright

TIPRANKS
·
02 Jul

Enliven Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $48 From $40

THOMSON REUTERS
·
02 Jul

CFO Benjamin Hohl Reports Disposal of Common Shares of Enliven Therapeutics Inc

Reuters
·
02 Jul

Enliven Therapeutics Inc. Conducted Annual Stockholders Meeting

Reuters
·
26 Jun

Chief Scientific Officer Joseph P. Lyssikatos Reports Disposal of Common Shares of Enliven Therapeutics Inc

Reuters
·
25 Jun

Enliven Therapeutics CEO Samuel Kintz Reports Disposal of Common Shares

Reuters
·
19 Jun

CFO Benjamin Hohl Reports Disposal of Common Shares of Enliven Therapeutics Inc

Reuters
·
18 Jun

Enliven Therapeutics Closes Public Offering

MT Newswires Live
·
17 Jun

Enliven Therapeutics Is Maintained at Outperform by Baird

Dow Jones
·
16 Jun

Enliven price target raised to $52 from $40 at Baird

TIPRANKS
·
16 Jun

Enliven Therapeutics Files Prospectus for Public Offering of Common Stock and Pre-Funded Warrants

Reuters
·
16 Jun

Promising Potential of Enliven Therapeutics’ ELVN-001: Buy Rating Reiterated with Strong Efficacy, Safety, and Market Opportunity

TIPRANKS
·
16 Jun

Optimistic Buy Rating for Enliven Therapeutics Driven by Promising ELVN-001 Data and Strategic Growth Plans

TIPRANKS
·
16 Jun

Enliven assigned with a Buy at Goldman Sachs

TIPRANKS
·
16 Jun

Enliven Therapeutics Up Over 16%, on Track for Largest Percent Increase Since April 2024 -- Data Talk

Dow Jones
·
14 Jun

Enliven Therapeutics Shares Reverse Premarket Losses, NOW up 2.6%

THOMSON REUTERS
·
13 Jun

Enliven Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

THOMSON REUTERS
·
13 Jun

Enliven Therapeutics Inc. Announces $200 Million Public Offering of Common Stock and Pre-Funded Warrants

Reuters
·
13 Jun

Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

THOMSON REUTERS
·
13 Jun